ConvaTec Targets Real World Edge in Diabetic Foot Ulcer Care With New ConvaNiox Study

ConvaTec Group plc (GB:CTEC) announced an update on their ongoing clinical study.

ConvaTec Group plc (CTEC) has announced a prospective, multi-centre real world study called “A Prospective, Multi-Centre, Observational, Real World Evidence Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing (ConvaNiox™) in the Treatment of Diabetes Related Foot Ulcers (DFUs).” The goal is to see how well the dressing works and how safe it is for hard-to-heal diabetic foot ulcers in everyday care.

The treatment being tested is ConvaNiox, a nitric oxide generating wound dressing used as a medical device. It is applied in place of the usual primary dressing, while patients still receive standard care for their diabetic foot ulcers.

The study is observational, so there is no random assignment to different treatments and no placebo group. Researchers will follow one cohort of patients over time in routine clinical settings to track healing outcomes and safety in a real world context.

The study was first submitted on 23 February 2026, with recruitment not yet started, signaling that sites and protocols are still being put in place. The latest update was filed on 16 March 2026, and final completion and primary completion dates have not yet been set, underscoring that timelines and enrollment progress remain early stage.

For investors, this update points to ConvaTec’s push to strengthen its advanced wound care portfolio, a key growth area in chronic disease management. Positive real world evidence could support wider adoption of ConvaNiox, improve pricing power versus rivals in diabetic wound care, and over time may boost sentiment toward CTEC relative to peers in advanced dressings and limb preservation.

The study is currently in the start-up phase and remains ongoing in the registry, with further details and future updates available on the ClinicalTrials portal.